Results 111 to 120 of about 106,022 (294)

Retatrutide-Induced Intractable Diarrhea

Annals of Internal Medicine: Clinical Cases
Gastrointestinal symptoms accompanying the use of glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide receptor-GLP-1 receptor co-agonists have been extensively catalogued.
Opeyemi Komolafe
doaj   +1 more source

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis

Journal of International Medical Research
Objective Glucagon-like peptide-1 receptor agonists are established for weight management and cardiovascular risk reduction, with emerging evidence for kidney protection.
Rong Huang, Bin Wang
doaj   +1 more source

Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults

The Laryngoscope, EarlyView.
Table 1 succinctly quantifies the time‑dependent association between GLP‑1RA/GIP therapy and laryngeal symptoms, demonstrating modest but statistically robust increases in outcomes such as cough and voice/resonance disorders by 6 months. It provides clinically actionable absolute risks, odds ratios, and hazard ratios that can directly inform counseling,
Priyanka Shah, David Kayekjian, Shaun A. Nguyen, Kirsten Meenan, Ashli K. O’Rourke   +4 more
wiley   +1 more source

Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and ...
Susanne A. Schneider, Divyani Garg, Vassilena Iankova, Thomas Klopstock   +3 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Chronic Cough

JAMA Otolaryngology–Head & Neck Surgery
Importance Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become substantially more popular as a medication to treat obesity and type 2 diabetes (T2D). Despite their known association with gastroesophageal reflux disease and vagal nerve stimulation, the association between GLP-1RAs and chronic cough ...
Gallagher, Tyler J., Razura, Diego E., Li, Albert, Kim, Ian, Vukkadala, Neelaysh, Barbu, Anca M.   +5 more
openaire   +2 more sources

High‐Fat Diet Exacerbates Neuropathology in a Transgenic Mouse Model of Multiple System Atrophy

Movement Disorders, EarlyView.
Abstract Background Multiple system atrophy (MSA) is a rare and devastating neurodegenerative disorder. Accumulating clinical and preclinical evidence suggests that diabetes and insulin resistance may adversely influence MSA pathophysiology. Objective We investigated the potential association between diabetes, impaired glucose homeostasis, and MSA ...
Marie‐Laure Arotcarena, Anna Delamarre, Miguel Lopez‐Cuina, Hugo Martin, Elio Balpe, Xavier Fioramonti, Erwan Bezard, Wassilios G. Meissner   +7 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis

Cureus
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) play a pivotal role in managing type 2 diabetes mellitus (T2DM), obesity, and other conditions, with proven benefits including, but not limited to, weight loss, glycemic control, and cardiovascular protection. However, their implications for arthritis are still debatable. GLP-1RAs may reduce systemic
openaire   +3 more sources

AI‐Driven Synthesis in Medicinal Chemistry: Integrating Large Language Models, Robotic Automation, and Sustainability Metrics to Accelerate Drug Discovery

Medicinal Research Reviews, EarlyView.
ABSTRACT Artificial intelligence (AI) is transforming synthetic chemistry from task‐specific predictors into integrated platforms that unify retrosynthesis, reaction optimization, and closed‐loop robotic automation. This review highlights how AI‐assisted planning and robotic execution shorten cycle times, reduce step counts, and improve route ...
Amit Gangwal, Antonio Lavecchia
wiley   +1 more source

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis

ACR Open Rheumatology
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA).
David A. Kellner, Elizabeth Dente, Vincent Tran, Travis Welsh, Victor Tran, Angshuman Saha, Joshua F. Baker, David A. Elashoff, Veena K. Ranganath   +8 more
doaj   +1 more source